BamSEC and AlphaSense Join Forces
Learn More

Vaxcyte Inc.

NASDAQ: PCVX    
Share price (8/15/25): $32.70    
Market cap (8/15/25): $4.245 billion
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.2
from 10-Q 6 pages Vaxcyte, Inc. Performance Contingent Stock Option Grant Notice
12/34/56
EX-10.1
from 10-Q 7 pages Vaxcyte, Inc. Psu Award Grant Notice
12/34/56
EX-10.22
from 10-K 74 pages Amended and Restated Lease Agreement
12/34/56
EX-10.27
from 10-K 10 pages Vaxcyte, Inc. Rsu Award Grant Notice – NON-U.S
12/34/56
EX-10.26
from 10-K 10 pages Vaxcyte, Inc. Stock Option Grant Notice – NON-U.S
12/34/56
EX-10.23
from 10-K 5 pages First Amendment to Lease
12/34/56
EX-10.21
from 10-K 3 pages Amendment No. 1 to the License Agreement Between Columbia Sutrovax, Inc. and the Regents of the University of California for Ucsd Case No. Sd2012-011
12/34/56
EX-10.19
from 10-K 44 pages Manufacturing Rights Agreement
12/34/56
EX-10.14
from 10-K 51 pages Pre-Commercial Services and Commercial Manufacturing Supply Agreement
12/34/56
EX-10.12
from 10-K 34 pages Master Services Agreement for Drug Product Development and Manufacturing
12/34/56
EX-10.3
from 10-Q 10 pages Third Amendment to Amended and Restated Sutrovax Agreement
12/34/56
EX-10.2
from 10-Q 9 pages Consent to Assignment and First Amendment
12/34/56
EX-10.1
from 10-Q 67 pages Certain Confidential Information Contained in This Document, Marked by [***], Has Been Omitted Because It Is Both (I) Not Material and (II) Is the Type That the Registrant Treats as Private or Confidential. Assignment and Assumption of Lease
12/34/56
EX-10.2
from 10-Q 6 pages Vaxcyte, Inc. Stock Option Grant Notice
12/34/56
EX-10.1
from 10-Q 30 pages Vaxcyte, Inc. 2020 Equity Incentive Plan Adopted by the Board of Directors: June 4, 2020 Approved by the Stockholders: June 4, 2020
12/34/56
EX-10
from 10-Q 28 pages Development and Manufacturing Services Agreement
12/34/56
EX-10
from 10-K 12 pages Certain Confidential Information Contained in This Document, Marked by [***], Has Been Omitted Because It Is Both (I) Not Material and (II) Is the Type That the Registrant Treats as Private or Confidential
12/34/56
EX-10
from 10-K 29 pages Supply Agreement
12/34/56
EX-10
from 10-K 31 pages Master Services Agreement for Drug Product Development and Manufacturing
12/34/56
EX-10
from 10-K 54 pages Development and Manufacturing Services Agreement
12/34/56